Omvik P, Lund-Johansen P
Medical Department School of Medicine, University of Bergen, Norway.
Eur J Clin Pharmacol. 1991;40(2):131-4. doi: 10.1007/BF00280066.
The long-term haemodynamic effect of sustained-release trimazosin (mean daily dose 418 mg) at rest and during exercise has been examined in 14 male patients (age 30-61 y) with previously untreated mild or moderate essential hypertension. Cardiac output (dye dilution), heart rate and intra-arterial blood pressure were measured supine and sitting at rest, and during bicycle exercise. After 11 months of trimazosin treatment the mean casual blood pressure was reduced from 165/106 mmHg to 147/92 mmHg. The intra-arterial systolic and diastolic pressure was reduced by 3-7% at rest and during 50, 100 and 150 W exercise. Total peripheral resistance was reduced by 8-14% and cardiac output was slightly higher (2-8%) in all situations. Stroke volume and heart rate remained unchanged, as did body fluid volumes (isotope dilution) and body weight. Side effects were minor and transient. Thus, the haemodynamic responses to trimazosin are similar to but weaker than those of other alpha 1-adrenoceptor blockers. The efficacy of the sustained-release formulation of trimazosin was low and daily doses above 600 mg are likely to be needed by many patients.
对14名（年龄30 - 61岁）既往未经治疗的轻度或中度原发性高血压男性患者，研究了缓释曲马唑嗪（平均日剂量418毫克）在静息和运动时的长期血流动力学效应。采用染料稀释法测量心输出量，测量静息仰卧位、静息坐位以及自行车运动时的心率和动脉内血压。曲马唑嗪治疗11个月后，平均偶测血压从165/106毫米汞柱降至147/92毫米汞柱。静息时以及50瓦、100瓦和150瓦运动时，动脉内收缩压和舒张压降低3 - 7%。在所有情况下，总外周阻力降低8 - 14%，心输出量略高（2 - 8%）。每搏输出量、心率、体液量（同位素稀释法）和体重均保持不变。副作用轻微且短暂。因此，曲马唑嗪的血流动力学反应与其他α1肾上腺素能受体阻滞剂相似，但较弱。曲马唑嗪缓释制剂的疗效较低，许多患者可能需要每日剂量超过600毫克。
